A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Official Title

A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Summary:

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR)
  • Duration of Response (DOR)
  • Progression-free Survival Rate (PFSR)
Secondary Outcome:
  • Safety as measured by incidence of AEs (Adverse Events)
  • Safety as measured by incidence of SAEs (Serious Adverse Events)
  • Tolerability as measured by incidence of AEs
  • Tolerability as measured by SAEs

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society